Litigants are close to reaching a settlement in a class-action lawsuit that alleged that the sleep aid U-Dream was sold when contaminated by an undisclosed ingredient, which caused injuries for some.
This meant that the product should not have been sold, according to the lawsuit. No admission of wrongdoing is in the proposed settlement.
The upshot for those who purchased U-Dream between Aug. 18, 2014 and the present is that they may be entitled to compensation ranging between $1,000 and $40,000 if they suffered injuries as a result. Those who were not injured but who want refunds and have proof of purchase may be entitled to payments exceeding $15. Those figures are projections, law firm Rice Harbut Elliott LLP said today in a news release.
"The precise amount of claims may be reduced depending upon the number of claims that are made and the cost of settlement administration fees," Rice Harbut Elliott LLP said.
The proposed settlement provides up to $2,734,485 to be paid to defendants, or people included in the class action, according to the law firm.
The representative plaintiff, James Douglas Ruckman has reached a tentative settlement with defendants, that either manufactured or distributed and sold the sleep aid: Biotrade Canada Ltd., London Drugs Limited, Rexall Pharmacy Group Ltd., Rexall/Pharma Plus Pharmacies Ltd., Whole Foods Market, Whole Foods Market Canada Inc. and PNP Pharmaceuticals Inc.
In order for that settlement to take effect, however, it needs to be approved by BC Supreme Court.
The full settlement terms and court documents are available at .
